[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-383683-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-383683-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","dual-targeting-pet-tracer-68-gaga-fapi-rgd-in-patients-with-lung-neoplasms-a-pilot-exploratory-study","Dual targeting PET tracer [68 Ga]Ga-FAPI-RGD in patients with lung neoplasms - a pilot exploratory study","","Early discovery, accurate diagnosis, and staging are critical for lung cancer management, yet PET tracers still need improvement. This pilot exploratory study evaluated feasibility of the dual-targeting heterodimeric tracer [68Ga]Ga-FAPI-RGD for lung neoplasms by comparing it with [18F]FDG and single-targeting tracers [68Ga]Ga-RGD and [68Ga]Ga-FAPI. Among 51 participants, dynamic scans showed rising uptake and an optimal 2-hour post-injection timepoint.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/healthcare/","Healthcare",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/dual-targeting-pet-tracer-68-gaga-fapi-rgd-in-patients-with-lung-neoplasms-a-pilot-exploratory-study/383683/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/dual-targeting-pet-tracer-68-gaga-fapi-rgd-in-patients-with-lung-neoplasms-a-pilot-exploratory-study/383683.png","ImageObject",300,407,{"name":42,"@type":43},"Aurelia","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-24",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",12,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What tracer strategy does this pilot study evaluate for lung neoplasms?","Question",{"text":63,"@type":64},"It evaluates [68Ga]Ga-FAPI-RGD, a dual-targeting PET tracer that recognizes fibroblast activation protein (FAP) and integrin αvβ3, and compares it with [18F]FDG and single-targeting tracers.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How many participants were included and what imaging comparisons were performed?",{"text":68,"@type":64},"All 51 participants underwent [68Ga]Ga-FAPI-RGD PET/CT; 44 also received [18F]FDG PET/CT within two weeks, with additional subsets receiving [68Ga]Ga-FAPI or [68Ga]Ga-RGD PET/CT.",{"name":70,"@type":61,"acceptedAnswer":71},"What scan timing was found optimal for dynamic imaging?",{"text":72,"@type":64},"For dynamic scans, the study identified 2 hours post-injection as the optimal timepoint for PET/CT scanning.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},383683,1790293861,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,110,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":108,"slug":109},7,40,"healthcare",{"id":111,"doc_module":4,"doc_module_name":25,"category_name":112,"show_sort_weight":113,"slug":114},8,"Research & Report",30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":107,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?_k=1776742907772140068","Ivyspring  \nInternational Publisher  \nTheranostics  \n2023; 13(9): 2979-2992. doi: 10.7150/thno.86007  \nResearch Paper  \nDual targeting PET tracer [68 Ga]Ga-FAPI-RGD inpatients with lung neoplasms: a pilot exploratory study  \nRongxi Wang1, Vivianne Jakobsson2,3,4, Jiarou Wang1, Tianzhi Zhao2,3,4, Xingtong Peng5, Bowen Li6,7, Jianchao Xue6,7, Naixin Liang6􀀍, Zhaohui Zhu1􀀍, Xiaoyuan Chen2,3,4,8􀀍, Jingjing Zhang2,3,4􀀍  \n1. Department of Nuclear Medicine, State Key Laboratory of Complex Severe and Rare Diseases, Beijing Key Laboratory of Molecular Targeted Diagnosis and Therapy in Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College, Beijing, China.  \n2. Departments of Diagnostic Radiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, 119074, Singapore.  \n3. Clinical Imaging Research Centre, Centre for Translational Medicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117599, Singapore.  \n4. Nanomedicine Translational Research Program, NUS Center for Nanomedicine, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117597, Singapore.  \n5. Eight-Year Program of Clinical Medicine, Peking Union Medical College Hospital (PUMCH), Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing 100730, China.  \n6. Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.  \n7. Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100730, China.  \n8. Departments of Chemical and Biomolecular Engineering and Biomedical Engineering, Faculty of Engineering, National University of Singapore, Singapore 117597, Singapore.  \n􀀍 Corresponding authors: Naixin Liang, MD, Department of Thoracic Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.1 Shuaifuyuan Wangfujing Dongcheng District, Beijing 100730, [China. Email: pumchnelson@163.com. Zhaohui Zhu](China. Email: pumchnelson@163.com. Zhaohui Zhu), MD, Ph.D., Department of Nuclear Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, No.  \n1 Shuaifuyuan, Wangfujing St, Dongcheng District, Beijing 100730, China. E-mail: [13611093752@163.com. Xiaoyuan](13611093752@163.com. Xiaoyuan) Chen, Ph.D., National University of Singapore, S9 Level 10, 4 Science Drive 2, Singapore 117544, Singapore. E-mail: [chen.shawn@nus.edu.sg. Jingjing Zhang](chen.shawn@nus.edu.sg. Jingjing Zhang), MD, Ph.D., National University of Singapore, S9 Level 10, 4 Science Drive 2, Singapore 117544, [Singapore. E-mail: j.zhang@nus.edu.sg](Singapore. E-mail: j.zhang@nus.edu.sg).  \n© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License ([https://creativecommons.org/licenses/by/4.0/](https://creativecommons.org/licenses/by/4.0/)). See [http://ivyspring.com/terms](http://ivyspring.com/terms) for full terms and conditions.  \nReceived: 2023.05.10; Accepted: 2023.05.10; Published: 2023.05.15  \nAbstract  \nRationale: Early discovery, accurate diagnosis, and staging of lung cancer is essential for patients to receive appropriate treatment. PET/CT has become increasingly recognized as a valuable imaging modality for these patients, but there remains room for improvement in PET tracers. We aimed to evaluate the feasibility of using [68Ga]Ga-FAPI-RGD, a dual-targeting heterodimeric PET tracer that recognizes both fibroblast activation protein (FAP) and integrin αvβ3 for detecting lung neoplasms, by comparing it with [18F]FDG and single-targeting tracers [68Ga]Ga-RGD and [68Ga]Ga-FAPI.  \nMethods: This was a pilot exploratory study of patients with suspected lung malignancies. All 51 participants underwent [68Ga]Ga-FAPI-RGD PET/CT, of whic","cbCaijuDaSh3UHCt","https://ap.wps.com/l/cbCaijuDaSh3UHCt","pdf",5742691,14,"English","# Abstract\n## Rationale\n## Methods\n## Results\n## Conclusion\n# Introduction","[{\"question\":\"What tracer strategy does this pilot study evaluate for lung neoplasms?\",\"answer\":\"It evaluates [68Ga]Ga-FAPI-RGD, a dual-targeting PET tracer that recognizes fibroblast activation protein (FAP) and integrin αvβ3, and compares it with [18F]FDG and single-targeting tracers.\"},{\"question\":\"How many participants were included and what imaging comparisons were performed?\",\"answer\":\"All 51 participants underwent [68Ga]Ga-FAPI-RGD PET/CT; 44 also received [18F]FDG PET/CT within two weeks, with additional subsets receiving [68Ga]Ga-FAPI or [68Ga]Ga-RGD PET/CT.\"},{\"question\":\"What scan timing was found optimal for dynamic imaging?\",\"answer\":\"For dynamic scans, the study identified 2 hours post-injection as the optimal timepoint for PET/CT scanning.\"}]","Dual targeting PET tracer [68 Ga]Ga-FAPI-RGD in patients with lung neoplasms - a pilot exploratory study | PDF",1790258738,35]